Removes Centralized Lab Dependency for $3.8 Billion Global Addressable Market forNETosis TestingHENDERSON, Nev., Aug. 12, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) (&#34;Volition&#34;), a multi-national

Removes Centralized Lab Dependency for $3.8 Billion Global Addressable Market forNETosis TestingHENDERSON, Nev., Aug. 12, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/VNRX">VNRX</a>) (&#34;Volition&#34;), a multi-national epigenetics company, today announces that results utilizing its lateral flow prototype are highly correlated with results utilizing Volition&#39;s established automated Nu.Q&#xAE; NETs test in critically ill sepsis patients1 , thereby expanding beyond centralized laboratory testing.
This new lateral flow finger prick sample test could be used to rapidly identify high-risk patients in the ER or at the bedside, thereby greatly expanding the potential market beyond centralized lab testing. It also has strong potential in countries worldwide with less developed centralized laboratory infrastructure.Dr Andrew Retter, Critical Care Lead and Medical Consultant, Volition, said: &#34;This is a huge step forward toward our goal of making Nu.Q&#xAE; NETs an easily accessible, cost-effective, minimally invasive test.&#34;We measured H3.1 nucleosomes in critically ill patients with sepsis, comparing a finger-prick sample read on a lateral flow device with our CE-marked laboratory assay on plasma. The two tracked closely, with a Spearman correlation of 0.85 and a Pearson correlation of 0.881.&#34;This is a significant step forward and a different kind of test from the one we have today. It materially reduces barriers to testing patients and facilitates nucleosome measurement at the bedside. &#34;The ability to rapidly identify high-risk patients at the Point-of-Care by quantifying their nucleosome levels using a finger-prick sample and simple lateral flow device could enable quicker clinical decision making and consequently better patient outcomes.&#34;Dr. Gaetan Michel, Chief Operating Officer, Volition said: &#34;This prototype technology has the exciting potential to strengthen our product portfolio. With recent estimates indicating approximately 166 million cases of sepsis worldwide, the potential addressable market is huge. All-cause sepsis related deaths in 2021 represented 31.5%2 of total global deaths, with the highest burden of mortality in lower-middle-income countries.&#34;&#34;This is a potential gamechanger, not only in diseases where time is critical such as sepsis, but also in significantly expanding potential use cases beyond traditional hospital infrastructure.  It also creates a compelling pathway into underserved low-income countries, where laboratory infrastructure may be weak or non-existent.&#34;By enabling decentralized testing, our total addressable market expands, and we are actively targeting NGO partnerships and strategic collaborations with companies operating in low income countries to accelerate commercialization and market penetration. &#34;We are excited to announce this breakthrough and look forward to sharing further details of the study and commercial updates throughout the year.&#34;Volition has previously announced <a xmlns="http://www.w3.org/1999/xhtml" href="https://ir.volition.com/news-events/press-releases/detail/847/volition-announces-groundbreaking-lateral-flow-test-for-point-of-care-quantification-of-nucleosomes" target="_blank" rel="nofollow">results</a> demonstrating not only correlation between whole venous blood (standard blood draw from the arm) samples utilizing its lateral flow prototype, and those of Volition&#39;s established automated Nu.Q&#xAE; nucleosome assay performed in a central laboratory but also more recently, the <a xmlns="http://www.w3.org/1999/xhtml" href="https://ir.volition.com/news-events/press-releases/detail/885/volition-announces-breakthrough-finger-prick-detection-of-nucleosomes-expanding-global-market-potential-for-sepsis-testing" target="_blank" rel="nofollow">successful detection</a> of nucleosomes in capillary blood.This study, part of the SUMMIT program, tested both capillary blood and plasma blood samples from hospital patients in Intensive Care using the lateral flow finger-prick prototype and the CE-marked automated assay and demonstrated significant correlation between the two formats. Results showed the feasibility of early detection of immune disruptions that can occur in a range of conditions including sepsis, simply and rapidly when using the test in a variety of settings (doctor&#39;s office, Emergency Department, Intensive Care Unit setting, or home self-test), without the need to send a blood sample to a hospital laboratory for testing.<ol xmlns="http://www.w3.org/1999/xhtml" type="1"><li xmlns="http://www.w3.org/1999/xhtml">Data on File</li><li xmlns="http://www.w3.org/1999/xhtml">Gray, Authia P et al.  Global, regional, and national sepsis incidence and mortality, 1990–2021: a systemic analysis. The Lancet Global Health, 2025; 13(12): e2013-e2026. <a xmlns="http://www.w3.org/1999/xhtml" href="https://doi.org/10.1016/s2214-109x(25)00356-0" target="_blank" rel="nofollow">doi: 10.1016/s2214-109x(25)00356-0</a></li></ol>About SUMMIT (Sepsis: addressing unmet needs for disease monitoring with a rapid test)This innovative project, aimed at developing a capillary blood-based lateral flow test for the early diagnosis of sepsis, is carried out with the financial support of the Walloon Region.About Volition&#39;s Nu.Q&#xAE; NETs Assay The Volition Nu.Q&#xAE; NETs assay is a chemiluminescent immunoassay (ChLIA) that currently runs on the Immunodiagnostic Systems (IDS) i10&#xAE; automated analyzer platform. It holds a CE Mark to aid in the detection and evaluation of diseases associated with NETosis and is available in 27 European Countries.About Volition <a xmlns="http://www.w3.org/1999/xhtml" href="https://volition.com/" target="_blank" rel="nofollow">Volition</a> is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.Volition&#39;s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.  The contents found at Volition&#39;s website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.Media Enquiries:Louise Batchelor, Volition, <a xmlns="http://www.w3.org/1999/xhtml" href="about:blank" target="_blank" rel="nofollow">mediarelations@volition.com</a> +44 (0)7557 774620Safe Harbor StatementStatements contained or referenced herein, including in any associated video or link, may be &#34;forward-looking statements&#34; within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are those that are not statements of historical fact and instead address predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance. Words such as &#34;expects,&#34; &#34;anticipates,&#34; &#34;intends,&#34; &#34;plans,&#34; &#34;aims,&#34; &#34;targets,&#34; &#34;believes,&#34; &#34;seeks,&#34; &#34;estimates,&#34; &#34;optimizing,&#34; &#34;potential,&#34; &#34;goal,&#34; &#34;suggests,&#34; &#34;could,&#34; &#34;would,&#34; &#34;should,&#34; &#34;may,&#34; &#34;will&#34; and similar expressions identify such statements.These forward-looking statements relate to, among other topics, Volition&#39;s expectations regarding revenue opportunities and growth; the effectiveness and availability of its blood-based diagnostic, prognostic and disease monitoring tests; and its ability to develop and successfully commercialize such test platforms for the early detection and monitoring of cancer and other diseases.Forward-looking statements are based on current expectations, estimates and projections about Volition&#39;s business, in part on assumptions made by management. They are not guarantees of future performance and involve risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those anticipated. These risks and uncertainties include, without limitation: the results of studies testing the efficacy of Volition&#39;s tests; failure to develop and commercialize its products, which may prevent it from executing its plan of operations; failure to obtain necessary regulatory clearances or approvals; failure to achieve healthcare system or insurance reimbursement; failure of the marketplace to accept its products; failure to secure adequate intellectual property protection; the highly competitive and rapidly evolving nature of the diagnostics and disease monitoring market, which may render its products obsolete; downturns in domestic and foreign economies; and other risks identified in Volition&#39;s most recent Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, and other documents filed with the Securities and Exchange Commission.Forward-looking statements are made as of the date hereof and, except as required by law, Volition undertakes no obligation to update them to reflect future events or circumstances.Nu.Q&#xAE;, Nucleosomics&#x2122;, Capture-PCR&#x2122;, Capture-Seq&#x2122; and rNuQ&#x2122; and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release or associated video or link are the property of their respective owners. Additionally, unless otherwise specified, all references to &#34;$&#34; refer to the legal currency of the United States of America.



<img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=LN24762&amp;sd=2026-08-12"></img> View original content:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/volition-demonstrates-utility-of-rapid-point-of-care-finger-prick-test-in-sepsis-patients-302849516.html" target="_blank">https://www.prnewswire.com/news-releases/volition-demonstrates-utility-of-rapid-point-of-care-finger-prick-test-in-sepsis-patients-302849516.html</a>SOURCE VolitionRx Limited

VNRX

Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients

VolitionRx's Finger-Prick NETs Test Shows Strong Lab Correlation, Expands TAM

<section class="insight" data-version="1">
 <section data-block="information">
 <h3>Information</h3>
 Removes Centralized Lab Dependency for $3.8 Billion Global Addressable Market forNETosis TestingHENDERSON, Nev., Aug. 12, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) (&amp;#34;Volition&amp;#34;), a multi-national
 </section>

 <section data-block="ai-summary-paragraph">
 <h3>AI Summary</h3>
 VolitionRx reported strong correlation between its lateral flow finger-prick NETs prototype and the automated Nu.Q NETs lab test in sepsis patients, signaling a shift toward decentralized, point-of-care testing. With a $3.8B NETosis TAM and ~166 million global sepsis cases, the initiative could broaden Volition&#039;s addressable market, particularly via NGO partnerships in low-infrastructure regions, potentially accelerating commercialization.
 </section>

 <section data-block="ai-summary-bullets">
 <h3>Key Points</h3>
 <ul><li>Lateral flow NETs test correlates with lab Nu.Q NETs (Spearman 0.85, Pearson 0.88).</li><li>Finger-prick bedside test enables rapid, high-risk patient identification.</li><li>Global sepsis market ~166 million cases; 31.5% mortality (2021).</li><li>TAM for NETosis testing cited at $3.8B; decentralized testing expands reach.</li></ul>
 </section>

 <section data-block="companies-mentioned">
 <h3>Companies Mentioned</h3>
 <ul><li>VolitionRx Limited (VNRX): Announces lateral flow prototype correlating with Nu.Q NETs; potential to broaden COA testing and market penetration.</li><li>Immunodiagnostic Systems Holdings plc (IDS): Nu.Q NETs assay runs on IDS i10 platform; reference to centralized-lab benchmark informs potential cross-ecosystem adoption.</li></ul>
 </section>

 <section data-block="category">
 <h3>Industry News</h3>
 Industry News. Fits as a product-development update with potential commercialization implications; not a confirmed revenue driver yet, but could influence sentiment and long-term valuation if translated into partnerships and sales.
 </section>

 <section data-block="market-moving">
 <h3>Market-Moving</h3>
 <ul><li>Correlation results (Spearman 0.85, Pearson 0.88) could lift near-term upside expectations.</li><li>$3.8B TAM for NETosis testing signals sizable long-run growth potential.</li><li>Bedside testing expands addressable market into low-infrastructure regions.</li><li>Volition pursuing NGO partnerships; year-end commercial updates anticipated.</li></ul>
 </section>

 <section data-block="key-facts">
 <h3>Key Facts</h3>
 <ul><li>Date of release: Aug 12, 2026.</li><li>Correlation between lateral flow test and central lab Nu.Q NETs: Spearman 0.85; Pearson 0.88.</li><li>Global sepsis cases: ~166 million.</li><li>All-cause sepsis deaths (2021): 31.5% of total global deaths.</li><li>Addressable market for NETosis testing: $3.8 billion.</li></ul>
 </section>

 <section data-block="trading-thesis">
 <h3>Trading Thesis</h3>
 Near-term upside for VNRX if commercialization timelines accelerate; monitor 6–12 months for partnerships and revenue.
 </section>
</section>


Removes Centralized Lab Dependency for $3.8 Billion Global Addressable Market forNETosis TestingHENDERSON, Nev., Aug. 12, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/VNRX">VNRX</a>) (&#34;Volition&#34;), a multi-national epigenetics company, today announces that results utilizing its lateral flow prototype are highly correlated with results utilizing Volition&#39;s established automated Nu.Q&#xAE; NETs test in critically ill sepsis patients1 , thereby expanding beyond centralized laboratory testing.
This new lateral flow finger prick sample test could be used to rapidly identify high-risk patients in the ER or at the bedside, thereby greatly expanding the potential market beyond centralized lab testing. It also has strong potential in countries worldwide with less developed centralized laboratory infrastructure.Dr Andrew Retter, Critical Care Lead and Medical Consultant, Volition, said: &#34;This is a huge step forward toward our goal of making Nu.Q&#xAE; NETs an easily accessible, cost-effective, minimally invasive test.&#34;We measured H3.1 nucleosomes in critically ill patients with sepsis, comparing a finger-prick sample read on a lateral flow device with our CE-marked laboratory assay on plasma. The two tracked closely, with a Spearman correlation of 0.85 and a Pearson correlation of 0.881.&#34;This is a significant step forward and a different kind of test from the one we have today. It materially reduces barriers to testing patients and facilitates nucleosome measurement at the bedside. &#34;The ability to rapidly identify high-risk patients at the Point-of-Care by quantifying their nucleosome levels using a finger-prick sample and simple lateral flow device could enable quicker clinical decision making and consequently better patient outcomes.&#34;Dr. Gaetan Michel, Chief Operating Officer, Volition said: &#34;This prototype technology has the exciting potential to strengthen our product portfolio. With recent estimates indicating approximately 166 million cases of sepsis worldwide, the potential addressable market is huge. All-cause sepsis related deaths in 2021 represented 31.5%2 of total global deaths, with the highest burden of mortality in lower-middle-income countries.&#34;&#34;This is a potential gamechanger, not only in diseases where time is critical such as sepsis, but also in significantly expanding potential use cases beyond traditional hospital infrastructure.  It also creates a compelling pathway into underserved low-income countries, where laboratory infrastructure may be weak or non-existent.&#34;By enabling decentralized testing, our total addressable market expands, and we are actively targeting NGO partnerships and strategic collaborations with companies operating in low income countries to accelerate commercialization and market penetration. &#34;We are excited to announce this breakthrough and look forward to sharing further details of the study and commercial updates throughout the year.&#34;Volition has previously announced <a xmlns="http://www.w3.org/1999/xhtml" href="https://ir.volition.com/news-events/press-releases/detail/847/volition-announces-groundbreaking-lateral-flow-test-for-point-of-care-quantification-of-nucleosomes" target="_blank" rel="nofollow">results</a> demonstrating not only correlation between whole venous blood (standard blood draw from the arm) samples utilizing its lateral flow prototype, and those of Volition&#39;s established automated Nu.Q&#xAE; nucleosome assay performed in a central laboratory but also more recently, the <a xmlns="http://www.w3.org/1999/xhtml" href="https://ir.volition.com/news-events/press-releases/detail/885/volition-announces-breakthrough-finger-prick-detection-of-nucleosomes-expanding-global-market-potential-for-sepsis-testing" target="_blank" rel="nofollow">successful detection</a> of nucleosomes in capillary blood.This study, part of the SUMMIT program, tested both capillary blood and plasma blood samples from hospital patients in Intensive Care using the lateral flow finger-prick prototype and the CE-marked automated assay and demonstrated significant correlation between the two formats. Results showed the feasibility of early detection of immune disruptions that can occur in a range of conditions including sepsis, simply and rapidly when using the test in a variety of settings (doctor&#39;s office, Emergency Department, Intensive Care Unit setting, or home self-test), without the need to send a blood sample to a hospital laboratory for testing.<ol xmlns="http://www.w3.org/1999/xhtml" type="1"><li xmlns="http://www.w3.org/1999/xhtml">Data on File</li><li xmlns="http://www.w3.org/1999/xhtml">Gray, Authia P et al.  Global, regional, and national sepsis incidence and mortality, 1990–2021: a systemic analysis. The Lancet Global Health, 2025; 13(12): e2013-e2026. <a xmlns="http://www.w3.org/1999/xhtml" href="https://doi.org/10.1016/s2214-109x(25)00356-0" target="_blank" rel="nofollow">doi: 10.1016/s2214-109x(25)00356-0</a></li></ol>About SUMMIT (Sepsis: addressing unmet needs for disease monitoring with a rapid test)This innovative project, aimed at developing a capillary blood-based lateral flow test for the early diagnosis of sepsis, is carried out with the financial support of the Walloon Region.About Volition&#39;s Nu.Q&#xAE; NETs Assay The Volition Nu.Q&#xAE; NETs assay is a chemiluminescent immunoassay (ChLIA) that currently runs on the Immunodiagnostic Systems (IDS) i10&#xAE; automated analyzer platform. It holds a CE Mark to aid in the detection and evaluation of diseases associated with NETosis and is available in 27 European Countries.About Volition <a xmlns="http://www.w3.org/1999/xhtml" href="https://volition.com/" target="_blank" rel="nofollow">Volition</a> is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.Volition&#39;s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.  The contents found at Volition&#39;s website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.Media Enquiries:Louise Batchelor, Volition, <a xmlns="http://www.w3.org/1999/xhtml" href="about:blank" target="_blank" rel="nofollow">mediarelations@volition.com</a> +44 (0)7557 774620Safe Harbor StatementStatements contained or referenced herein, including in any associated video or link, may be &#34;forward-looking statements&#34; within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are those that are not statements of historical fact and instead address predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance. Words such as &#34;expects,&#34; &#34;anticipates,&#34; &#34;intends,&#34; &#34;plans,&#34; &#34;aims,&#34; &#34;targets,&#34; &#34;believes,&#34; &#34;seeks,&#34; &#34;estimates,&#34; &#34;optimizing,&#34; &#34;potential,&#34; &#34;goal,&#34; &#34;suggests,&#34; &#34;could,&#34; &#34;would,&#34; &#34;should,&#34; &#34;may,&#34; &#34;will&#34; and similar expressions identify such statements.These forward-looking statements relate to, among other topics, Volition&#39;s expectations regarding revenue opportunities and growth; the effectiveness and availability of its blood-based diagnostic, prognostic and disease monitoring tests; and its ability to develop and successfully commercialize such test platforms for the early detection and monitoring of cancer and other diseases.Forward-looking statements are based on current expectations, estimates and projections about Volition&#39;s business, in part on assumptions made by management. They are not guarantees of future performance and involve risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those anticipated. These risks and uncertainties include, without limitation: the results of studies testing the efficacy of Volition&#39;s tests; failure to develop and commercialize its products, which may prevent it from executing its plan of operations; failure to obtain necessary regulatory clearances or approvals; failure to achieve healthcare system or insurance reimbursement; failure of the marketplace to accept its products; failure to secure adequate intellectual property protection; the highly competitive and rapidly evolving nature of the diagnostics and disease monitoring market, which may render its products obsolete; downturns in domestic and foreign economies; and other risks identified in Volition&#39;s most recent Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, and other documents filed with the Securities and Exchange Commission.Forward-looking statements are made as of the date hereof and, except as required by law, Volition undertakes no obligation to update them to reflect future events or circumstances.Nu.Q&#xAE;, Nucleosomics&#x2122;, Capture-PCR&#x2122;, Capture-Seq&#x2122; and rNuQ&#x2122; and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release or associated video or link are the property of their respective owners. Additionally, unless otherwise specified, all references to &#34;$&#34; refer to the legal currency of the United States of America.



<img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=LN24762&amp;sd=2026-08-12"></img> View original content:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/volition-demonstrates-utility-of-rapid-point-of-care-finger-prick-test-in-sepsis-patients-302849516.html" target="_blank">https://www.prnewswire.com/news-releases/volition-demonstrates-utility-of-rapid-point-of-care-finger-prick-test-in-sepsis-patients-302849516.html</a>SOURCE VolitionRx Limited

VolitionRx reported strong correlation between its lateral flow finger-prick NETs prototype and the automated Nu.Q NETs lab test in sepsis patients, signaling a shift toward decentralized, point-of-care testing. With a $3.8B NETosis TAM and ~166 million global sepsis cases, the initiative could broaden Volition's addressable market, particularly via NGO partnerships in low-infrastructure regions, potentially accelerating commercialization.

News insight

Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients

AI summary

Sentiment rationale

Key facts

Industry News